121 related articles for article (PubMed ID: 3240439)
1. Sparsomycin analogs. IV. Synthesis and antitumor activity of pyrimidine-5-carboxamides and (E)-beta-(pyrimidin-5-yl)acrylamides.
Kanatomo S; Wada A; Yomei M; Hase T; Nagai S; Fukuda S; Tanaka M; Sasaki T
Chem Pharm Bull (Tokyo); 1988 Jun; 36(6):2042-9. PubMed ID: 3240439
[No Abstract] [Full Text] [Related]
2. Sparsomycin analogs. V. Synthesis and antitumor activity of (E)-beta-(pyrimidin-5-yl)acrylamides.
Kanatomo S; Wada A; Hamaoka Y; Nagai S; Fukuda S; Tanaka M; Sasaki T
Chem Pharm Bull (Tokyo); 1988 Nov; 36(11):4421-5. PubMed ID: 3246010
[No Abstract] [Full Text] [Related]
3. Sparsomycin analogs. VI. Synthesis and antitumor activity of octylsparsomycin analogs.
Kanatomo S; Hase T; Wada A; Ohki K; Nagai S; Tanaka M; Sasaki T
Chem Pharm Bull (Tokyo); 1989 Mar; 37(3):688-91. PubMed ID: 2752478
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of sparsomycin analogs as potential antitumor agents.
Dubois RJ; Lin CC; Michel BL
J Pharm Sci; 1975 May; 64(5):825-9. PubMed ID: 1151655
[TBL] [Abstract][Full Text] [Related]
5. Sparsomycin analogs. III. Synthesis and biological activities of (E)-beta-(6-methyluracil-5-yl)acrylic acid derivatives.
Kanatomo S; Nagai S; Ohki K; Hase T; Nomura C; Okezaki E
Chem Pharm Bull (Tokyo); 1984 Nov; 32(11):4625-31. PubMed ID: 6532561
[No Abstract] [Full Text] [Related]
6. Chemical and biological aspects of sparsomycin, an antibiotic from Streptomyces.
Ottenheijm HC; van den Broek LA; Ballesta JP; Zylicz Z
Prog Med Chem; 1986; 23():219-68. PubMed ID: 3310108
[No Abstract] [Full Text] [Related]
7. Importance of the hydrophobic sulfoxide substituent on nontoxic analogs of sparsomycin.
Ash RJ; Fite LD; Beight DW; Flynn GA
Antimicrob Agents Chemother; 1984 Apr; 25(4):443-5. PubMed ID: 6375553
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ
J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932
[TBL] [Abstract][Full Text] [Related]
9. Sparsomycin analogs. II. Synthesis and biological activities of 5-carboxy-6-methyluracil derivatives.
Kanatomo S; Nagai S; Hase T; Ohki K; Nomura C; Okezaki E
Chem Pharm Bull (Tokyo); 1983 Jan; 31(1):135-43. PubMed ID: 6850930
[No Abstract] [Full Text] [Related]
10. Inhibition of Trypanosoma brucei brucei peptidyl transferase activity by sparsomycin analogs and effects on trypanosome protein synthesis and proliferation.
Bitonti AJ; Kelly SE; Flynn GA; McCann PP
Biochem Pharmacol; 1985 Sep; 34(17):3055-60. PubMed ID: 4038323
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of protein biosynthesis: the first active sparsomycin analog.
Vince R; Brownell J; Lee CK
Biochem Biophys Res Commun; 1977 Apr; 75(3):563-7. PubMed ID: 856177
[No Abstract] [Full Text] [Related]
12. The development of sparsomycin as an anti-tumour drug.
Ottenheijm HC; van den Broek LA
Anticancer Drug Des; 1988 Mar; 2(4):333-7. PubMed ID: 3365303
[TBL] [Abstract][Full Text] [Related]
13. Necessity of the sulfoxide moiety for the biochemical and biological properties of an analog of sparsomycin.
Flynn GA; Ash RJ
Biochem Biophys Res Commun; 1983 Jul; 114(1):1-7. PubMed ID: 6349625
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and activity of pyrimidinylpropenamide antibiotics: the alkyl analogues of sparsomycin.
Nakajima N; Enomoto T; Watanabe T; Matsuura N; Ubukata M
Biosci Biotechnol Biochem; 2003 Dec; 67(12):2556-66. PubMed ID: 14730133
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships of sparsomycin: modification at the hydroxyl group.
Lázaro E; van den Broek LA; Ottenheijm HC; Lelieveld P; Ballesta JP
Biochimie; 1987 Aug; 69(8):849-56. PubMed ID: 3122847
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of pyrimidine-based dual inhibitors of human epidermal growth factor receptor 1 (HER-1) and HER-2 tyrosine kinases.
Cha MY; Lee KO; Kang SJ; Jung YH; Song JY; Choi KJ; Byun JY; Lee HJ; Lee GS; Park SB; Kim MS
J Med Chem; 2012 Mar; 55(6):2846-57. PubMed ID: 22372864
[TBL] [Abstract][Full Text] [Related]
17. Lipophilic analogues of sparsomycin as strong inhibitors of protein synthesis and tumor growth: a structure-activity relationship study.
van den Broek LA; Lázaro E; Zylicz Z; Fennis PJ; Missler FA; Lelieveld P; Garzotto M; Wagener DJ; Ballesta JP; Ottenheijm HC
J Med Chem; 1989 Aug; 32(8):2002-15. PubMed ID: 2754719
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and antineoplastic effects of furo[3,4-d]pyrimidine derivatives.
Machoń Z; Cieplik J
Pol J Pharmacol Pharm; 1988; 40(2):201-8. PubMed ID: 3237569
[TBL] [Abstract][Full Text] [Related]
19. The chiral synthesis and biochemical properties of electron rich phenolic sulfoxide analogs of sparsomycin.
Flynn GA; Ash RJ
Biochem Biophys Res Commun; 1990 Jan; 166(2):673-80. PubMed ID: 2405852
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.
Wang Q; Liu F; Qi S; Qi Z; Yan XE; Wang B; Wang A; Wang W; Chen C; Liu X; Jiang Z; Hu Z; Wang L; Wang W; Ren T; Zhang S; Yun CH; Liu Q; Liu J
Eur J Med Chem; 2018 Apr; 150():366-384. PubMed ID: 29544149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
